" class="no-js "lang="en-US"> Mark Appleton - Medtech Alert
Friday, October 03, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Mark Appleton

Mark Appleton

About Mark Appleton

Mark joined H.E.L Group in 1991 after completing a Ph.D. at Imperial College London. In his current role, Mark drives the innovation and product concept pipeline, which feeds into new product development and launch process. With over 30 years at H.E.L Group, Mark has been instrumental in developing almost all of the Company’s products and services…

Related Story

Appointments

 H.E.L Group Strengthens Leadership Team to Focus on New Product Development and Enhanced Customer Support | Pharmtech Focus

H.E.L Group Strengthens Leadership Team to Focus on New Product Development and Enhanced Customer Support

September 6 2022

H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimisation, […]